<DOC>
	<DOCNO>NCT01689571</DOCNO>
	<brief_summary>The study design look safety , tolerability efficacy 2 different dos study drug ( CHF6001 , PDE4 inhibitor ) asthmatic , give inhalation , day 9 day . The efficacy evaluate measure protective effect CHF 6001 allergen challenge .</brief_summary>
	<brief_title>A Study Evaluate Efficacy After Allergen Challenge , Safety Tolerability Inhaled CHF6001 DPI Asthmatics</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>write informed consent obtain Non smoke exsmokers least 1 year prior study entry Males females 18 60 year inclusive Body Mass Index 18 32 kg/m2 Ability train proper use inhalation device perform spirometry With mild moderate allergic asthma define GINA guideline , steroid naive Atopy least one common aeroallergen Positive allergeninduced Early Asthmatic Response Late Asthmatic Response screen Ability produce adequate sputum sample Postmenopausal woman , woman childbearing potential male female childbearing potential willing ( partner ) use reliable method contraception . Worsening asthma respiratory tract infection prior study entry History lifethreatening asthma hospitalization asthma prior study entry Pregnant lactate woman History clinically significant hypotensive episode fainting , dizziness lightheadedness History symptom clinically relevant neurologic disease Symptomatic hay fever Unstable concurrent disease may impact feasibility study Use systemic corticosteroid , nebulised bronchodilator oral beta2agonist Use leukotrienes modifier , roflumilast cromoglycate Use long act beta2agonist inhale corticosteroid Use shortacting longacting nonsedatives antihistamine Use medication treatment allergic asthma salbutamol Having receive investigational medicinal drug within 30 day prior study entry Blood drawn least 250 ml previous 45 day Ongoing use tobacco Other lung disease Recent history alcohol dependency Inability comply study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PDE4 inhibitor</keyword>
	<keyword>Allergen Challenge</keyword>
	<keyword>Asthma</keyword>
</DOC>